Literature DB >> 26450277

Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH).

Cheng Jun Jin1, Cathrin Sellmann1, Anna Janina Engstler1, Doreen Ziegenhardt1, Ina Bergheim1.   

Abstract

Overnutrition, insulin resistance and an impaired intestinal barrier function are discussed as critical factors in the development of non-alcoholic fatty liver disease. Not only butyrate-producing probiotics as well as supplementation of sodium butyrate (SoB) have been suggested to bear protective effects on liver damage of various aetiologies. However, whether an oral consumption of SoB has a protective effect on Western-style diet (WSD)-induced non-alcoholic steatohepatitis (NASH) and if so molecular mechanism involved has not yet been determined. Eight-week-old C57BL/6J mice were pair-fed either a liquid control or WSD±0·6 g/kg body weight SoB. After 6 weeks, markers of liver damage, inflammation, toll-like receptor (TLR)-4 signalling, lipid peroxidation and glucose as well as lipid metabolism were determined in the liver tissue. Tight junction protein levels were determined in the duodenal tissue. SoB supplementation had no effects on the body weight gain or liver weight of WSD-fed mice, whereas liver steatosis and hepatic inflammation were significantly decreased (e.g. less inflammatory foci and neutrophils) when compared with mice fed only a WSD. Tight junction protein levels in duodenum, hepatic mRNA expression of TLR-4 and sterol regulatory element-binding protein 1c were altered similarly in both WSD groups when compared with controls, whereas protein levels of myeloid differentiation primary response gene 88, inducible nitric oxide synthase, 4-hydroxynonenal protein adducts and F4/80 macrophages were only significantly induced in livers of mice fed only the WSD. In summary, these data suggest that an oral supplementation of SoB protects mice from inflammation in the liver and thus from the development of WSD-induced NASH.

Entities:  

Keywords:  Hepatic inflammation; Inducible nitric oxide synthase; Non-alcoholic fatty liver disease; Reactive oxygen species; Sodium butyrate

Mesh:

Substances:

Year:  2015        PMID: 26450277     DOI: 10.1017/S0007114515003621

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  42 in total

Review 1.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

2.  Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.

Authors:  Da Zhou; Qin Pan; Feng-Zhi Xin; Rui-Nan Zhang; Chong-Xin He; Guang-Yu Chen; Chang Liu; Yuan-Wen Chen; Jian-Gao Fan
Journal:  World J Gastroenterol       Date:  2017-01-07       Impact factor: 5.742

Review 3.  Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet.

Authors:  Zeinab Mokhtari; Deanna L Gibson; Azita Hekmatdoost
Journal:  Adv Nutr       Date:  2017-03-15       Impact factor: 8.701

4.  Butyrate restores HFD-induced adaptations in brain function and metabolism in mid-adult obese mice.

Authors:  I A C Arnoldussen; M Wiesmann; C E Pelgrim; E M Wielemaker; W van Duyvenvoorde; P L Amaral-Santos; L Verschuren; B J F Keijser; A Heerschap; R Kleemann; P Y Wielinga; A J Kiliaan
Journal:  Int J Obes (Lond)       Date:  2017-02-21       Impact factor: 5.095

Review 5.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 6.  Microbiome-Mediated Effects of the Mediterranean Diet on Inflammation.

Authors:  Melisa A Bailey; Hannah D Holscher
Journal:  Adv Nutr       Date:  2018-05-01       Impact factor: 8.701

Review 7.  Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?

Authors:  Naga S Betrapally; Patrick M Gillevet; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2016-03-04       Impact factor: 22.682

Review 8.  Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.

Authors:  Sena Bluemel; Brandon Williams; Rob Knight; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-29       Impact factor: 4.052

9.  Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model.

Authors:  Prasant Kumar Jena; Lili Sheng; Yongchun Li; Yui-Jui Yvonne Wan
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

Review 10.  Intestinal Barrier and Permeability in Health, Obesity and NAFLD.

Authors:  Piero Portincasa; Leonilde Bonfrate; Mohamad Khalil; Maria De Angelis; Francesco Maria Calabrese; Mauro D'Amato; David Q-H Wang; Agostino Di Ciaula
Journal:  Biomedicines       Date:  2021-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.